31 October 2019
Visiongain has launched a new pharma report Attention Deficit Hyperactivity Disorder Drugs Market: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.
The global attention deficit hyperactivity disorder is anticipated to witness strong growth during the forecast period. Factors such as the growing prevalence of the ADHD cases in adults and children, growing awareness coupled with support from the government as well as rising regulatory approvals will drive market growth.
The lead analyst of the report commented "The global attention deficit disorder market is one that is driven by innovation. This is vital for maintaining the rich pipeline of ADHD drugs seen in the market today. There is increasing focus to identify and treat ADHD that currently are undertreated and try to serve these neglected markets. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market. This prevents stagnation within the market and will help drive the growth of attention deficit disorder market."
Leading companies featured in the report include Eli Lilly, Johnson and Johnson, Lupin Limited, Mallinckrodt & Co., Neos Therapeutics, Pfizer Inc., Purdue Pharma L.P., Takeda Pharmaceuticals and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Gene Amplification Technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.
05 December 2022
The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.
01 December 2022
The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.
01 December 2022
The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.